For research use only. Not for therapeutic Use.
Romlusevimab（Cat No.:I041528）is an investigational monoclonal antibody being studied for its potential use in treating COVID-19. It targets the spike protein of the SARS-CoV-2 virus, which is responsible for the virus’s ability to infect human cells. By binding to the spike protein, romlusevimab prevents the virus from entering host cells, thereby reducing the risk of infection or the severity of symptoms. It is being tested in clinical trials as a treatment option for individuals at high risk of severe COVID-19, offering an additional tool in the fight against the pandemic.
| Catalog Number | I041528 |
| CAS Number | 2509447-08-7 |
| Purity | ≥95% |
